Chondrosarcoma- Pipeline Insight, 2025
Description
DelveInsight’s, “Chondrosarcoma- Pipeline Insight, 2025” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Chondrosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chondrosarcoma: Overview
Chondrosarcoma is a rare type of cancer that originates in the cartilage cells. It is the second most common primary malignancy of bone, typically affecting adults aged 40–70. Unlike other bone cancers, chondrosarcoma is slow-growing but can vary significantly in aggressiveness depending on the subtype. It most often occurs in the pelvis, ribs, and long bones like the femur and humerus. Subtypes include conventional, clear cell, dedifferentiated, and mesenchymal chondrosarcoma, each with distinct characteristics and behaviors.
Patients with chondrosarcoma often present with a dull, persistent pain in the affected area, which may worsen over time. Other symptoms include localized swelling or a palpable mass, restricted joint movement, or nerve compression if the tumor presses against nearby structures. In more aggressive forms, systemic symptoms like weight loss and fatigue may appear. Depending on the tumor's location, it can also lead to fractures or functional impairments.
The exact cause of chondrosarcoma remains unclear, but several risk factors have been identified. It can arise de novo or develop from preexisting benign cartilage tumors like enchondromas or osteochondromas. Genetic conditions, such as Ollier disease and Maffucci syndrome, increase the risk. Mutations in genes like IDH1, IDH2, and COL2A1 are commonly associated with the disease. Environmental factors, such as radiation exposure, may also play a role in rare cases.
Diagnosing chondrosarcoma begins with a thorough clinical evaluation and imaging studies. X-rays typically reveal a lytic lesion with calcifications, while MRI helps assess the tumor’s size, extent, and relationship to surrounding tissues. A CT scan is useful for evaluating mineralization and cortical bone involvement. Definitive diagnosis requires a biopsy, where a tissue sample is analyzed for histological grading. Higher-grade tumors have greater cellular atypia, mitotic activity, and necrosis, correlating with worse prognosis.
The primary treatment for chondrosarcoma is surgical resection with wide margins to minimize recurrence. The type of surgery depends on the tumor's size, grade, and location. Low-grade tumors may require curettage or intralesional excision, while high-grade or aggressive tumors necessitate extensive procedures, potentially including amputation. Chemotherapy and radiation are typically ineffective for conventional chondrosarcomas but may benefit certain subtypes like mesenchymal or dedifferentiated forms. Targeted therapies based on molecular alterations are being explored in clinical trials.
""Chondrosarcoma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chondrosarcoma pipeline landscape is provided which includes the disease overview and Chondrosarcoma treatment guidelines. The assessment part of the report embraces, in depth Chondrosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chondrosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chondrosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chondrosarcoma Emerging Drugs
Trabectedin (Yondelis) is an anti-tumor agent of marine origin discovered in the caribbean tunicate, ecteinascidia turbinata. It is formulated as lyophilized powder for solution for injection for intravenous route of administration. Yondelis is indicated for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Mesenchymal Chondrosarcoma.
Further product details are provided in the report……..
Chondrosarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Chondrosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Chondrosarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chondrosarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chondrosarcoma drugs.
Chondrosarcoma Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Chondrosarcoma: Overview
Chondrosarcoma is a rare type of cancer that originates in the cartilage cells. It is the second most common primary malignancy of bone, typically affecting adults aged 40–70. Unlike other bone cancers, chondrosarcoma is slow-growing but can vary significantly in aggressiveness depending on the subtype. It most often occurs in the pelvis, ribs, and long bones like the femur and humerus. Subtypes include conventional, clear cell, dedifferentiated, and mesenchymal chondrosarcoma, each with distinct characteristics and behaviors.
Patients with chondrosarcoma often present with a dull, persistent pain in the affected area, which may worsen over time. Other symptoms include localized swelling or a palpable mass, restricted joint movement, or nerve compression if the tumor presses against nearby structures. In more aggressive forms, systemic symptoms like weight loss and fatigue may appear. Depending on the tumor's location, it can also lead to fractures or functional impairments.
The exact cause of chondrosarcoma remains unclear, but several risk factors have been identified. It can arise de novo or develop from preexisting benign cartilage tumors like enchondromas or osteochondromas. Genetic conditions, such as Ollier disease and Maffucci syndrome, increase the risk. Mutations in genes like IDH1, IDH2, and COL2A1 are commonly associated with the disease. Environmental factors, such as radiation exposure, may also play a role in rare cases.
Diagnosing chondrosarcoma begins with a thorough clinical evaluation and imaging studies. X-rays typically reveal a lytic lesion with calcifications, while MRI helps assess the tumor’s size, extent, and relationship to surrounding tissues. A CT scan is useful for evaluating mineralization and cortical bone involvement. Definitive diagnosis requires a biopsy, where a tissue sample is analyzed for histological grading. Higher-grade tumors have greater cellular atypia, mitotic activity, and necrosis, correlating with worse prognosis.
The primary treatment for chondrosarcoma is surgical resection with wide margins to minimize recurrence. The type of surgery depends on the tumor's size, grade, and location. Low-grade tumors may require curettage or intralesional excision, while high-grade or aggressive tumors necessitate extensive procedures, potentially including amputation. Chemotherapy and radiation are typically ineffective for conventional chondrosarcomas but may benefit certain subtypes like mesenchymal or dedifferentiated forms. Targeted therapies based on molecular alterations are being explored in clinical trials.
""Chondrosarcoma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chondrosarcoma pipeline landscape is provided which includes the disease overview and Chondrosarcoma treatment guidelines. The assessment part of the report embraces, in depth Chondrosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chondrosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chondrosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Chondrosarcoma.
This segment of the Chondrosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chondrosarcoma Emerging Drugs
- Trabectedin: PharmaMar
Trabectedin (Yondelis) is an anti-tumor agent of marine origin discovered in the caribbean tunicate, ecteinascidia turbinata. It is formulated as lyophilized powder for solution for injection for intravenous route of administration. Yondelis is indicated for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Mesenchymal Chondrosarcoma.
- Seclidemstat: Salarius Pharmaceuticals, LLC
- Ifosfamide: Atlanthera
Further product details are provided in the report……..
Chondrosarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Chondrosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chondrosarcoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Chondrosarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chondrosarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chondrosarcoma drugs.
Chondrosarcoma Report Insights
- Chondrosarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chondrosarcoma drugs?
- How many Chondrosarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chondrosarcoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chondrosarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chondrosarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- PharmaMar
- Salarius Pharmaceuticals, LLC
- Atlanthera
- Iovance Biotherapeutics
- Ipsen
- Trabectedin
- Seclidemstat
- Ifosfamide
- LN-145
- Tazemetostat
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Chondrosarcoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Chondrosarcoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Trabectedin: PharmaMar
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Seclidemstat: Salarius Pharmaceuticals, LLC
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Ifosfamide: Atlanthera
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Chondrosarcoma Key Companies
- Chondrosarcoma Key Products
- Chondrosarcoma- Unmet Needs
- Chondrosarcoma- Market Drivers and Barriers
- Chondrosarcoma- Future Perspectives and Conclusion
- Chondrosarcoma Analyst Views
- Chondrosarcoma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
